V72P10
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for V72P10, covering 2014-03-11 to 2014-03-11. Get the full timeline:
Most recent: Clinical Trial Update: Assessment of Antibody Persistence at Eighteen Months After the Completion of the Vaccination Course in Study V72P10 [Phase 2, Phase 3]